Nicox Partners with Glaukos for NCX 1728 Research
Recently, Nicox SA, a global ophthalmology company, announced an exclusive partnership with Glaukos Corporation. This collaboration centers on the research and global licensing of NCX 1728, a groundbreaking compound aimed at treating serious eye conditions like glaucoma and various retinal diseases.
Highlights of the Agreement
The partnership grants Glaukos exclusive rights to license NCX 1728 on a global scale. This includes upfront payments along with milestone options and future royalties. The intention is to harness Glaukos’ expertise in treating eye disorders and their state-of-the-art drug delivery systems to refine NCX 1728 for a range of uses, such as lowering intraocular pressure and offering neuroprotection.
Research Activities Supported by Glaukos
According to the agreement, Glaukos will completely finance the preclinical research required to assess NCX 1728. This research aims to investigate the compound’s effectiveness in glaucoma treatment and its potential applications in retinal diseases. A Joint Steering Committee will oversee this joint research initiative.
Strategic Development Goals
In this strategic collaboration, Nicox will continue to focus on the advancement of its leading drug candidate, NCX 470, which is in Phase 3 development. NCX 470 is another NO-donating molecule designed to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
More About NCX 1728
NCX 1728 is part of an innovative class of NO-donating phosphodiesterase-5 (PDE5) inhibitors. This special formulation is designed to enhance and extend the effects of nitric oxide (NO), which is crucial for treating various ocular conditions. By combining NO donation with PDE5 inhibition, it aims for better therapeutic results, especially in cases that require prolonged effects on reducing intraocular pressure.
About Nicox SA
Based in Sophia Antipolis, France, Nicox SA is committed to developing advanced solutions that enhance vision preservation and ocular health. Their product lineup includes revenue-generating items like VYZULTA®, which is licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE®, which is licensed in several regions for treating allergic conjunctivitis.
Looking Ahead
This partnership between Nicox and Glaukos holds great promise not just for the companies involved but also for patients battling glaucoma and retinal diseases. With Glaukos taking the lead on preclinical research, both companies aim to unlock the full therapeutic potential of NCX 1728, paving the way for innovative treatments in the ophthalmic field.
Frequently Asked Questions
What is NCX 1728?
NCX 1728 is a new nitric oxide-donating phosphodiesterase-5 inhibitor designed for treating glaucoma and retinal diseases.
How does this partnership benefit patients?
This collaboration aims to create effective treatments that could significantly enhance patients' conditions related to intraocular pressure and neuroprotection.
What is Glaukos' role in this agreement?
Glaukos will fund and manage the preclinical research for NCX 1728 and has the option to license the compound for global development.
What is the current status of Nicox's development pipeline?
Nicox is currently focused on Phase 3 development of NCX 470, which is its lead candidate for open-angle glaucoma management.
Where can I find more information about Nicox?
You can find additional details about Nicox's products and developments on their official website.
